文献速递外周动脉疾病

Absorb依维莫司洗脱生物可吸收支架在亚洲CLTI患者中的早期与中期经验:DISAPEAR注册研究一年临床与影像结果

Early and Midterm Experience With the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Asian Patients With Chronic Limb-Threatening Ischemia: One-Year Clinical and Imaging Outcomes From the DISAPEAR Registry.
PubMed 文献 · J Endovasc Ther · 2020-05-29

DISAPEAR注册研究回顾性分析了41例因膝下原发病变(狭窄>50%)导致慢性肢体威胁性缺血(CLTI)的亚洲患者,共53处病变置入69枚Absorb生物可吸收支架。技术成功率100%,6个月和12个月一期通畅率分别为95%和86%,免于临床驱动靶病变血运重建率分别为98%和93%,免于大截肢率均为98%,12个月时79%的Rutherford 5/6级患者伤口愈合。

要点

  • Absorb BVS在亚洲CLTI患者膝下复杂病变中技术成功率达100%,1年通畅率良好。
  • 12个月免于CD-TLR为93%,免于大截肢为98%,截肢无生存率为85%。
  • 79%的Rutherford 5/6级患者在12个月内实现伤口愈合。

核心结论

  • Absorb BVS在合并复杂膝下病变的CLTI患者中展现出良好的一年期通畅率和临床结局。

研究设计与样本

  • 回顾性分析DISAPEAR注册研究中41例CLTI患者(中位年龄64岁,23例男性),因>50%膝下原发病变(n=53)于2012年8月至2017年6月接受Absorb BVS治疗。

主要发现

  • 6个月和12个月一期通畅率分别为95%和86%。
  • 6个月和12个月免于临床驱动靶病变血运重建率分别为98%和93%。
  • 6个月和12个月免于大截肢率均为98%,截肢无生存率分别为93%和85%。
  • 12个月时79%的Rutherford 5/6级患者实现伤口愈合。
  • 30天内无死亡,技术成功率为100%。

临床怎么用

  • 对于合并复杂膝下病变的CLTI患者,Absorb BVS可作为血运重建的一种选择,但需结合患者个体情况评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose: To report an experience with the Absorb bioresorbable vascular scaffold (BVS) in an Asian cohort with chronic limb-threatening ischemia (CLTI) from the DISAPEAR (Drug Impregnated Bioresorbable Stent in Asian Population Extremity Arterial Revascularization) registry. Materials and Methods: A retrospective analysis was conducted of 41 patients (median age 64 years; 23 men) with CLTI owing to >50% de novo infrapopliteal lesions (n=53) treated with the Absorb BVS between August 2012 and June 2017. The majority of patients (37, 90%) had diabetes, 24 (59%) had ischemic heart disease, and 39 (95%) had Rutherford category 5/6 ischemia with tissue loss. The mean lesion length was 22.7±17.2 mm; 10 (24%) lesions were severely calcified. Assessments included technical success, primary patency, freedom from clinically-driven target lesion revascularization (CD-TLR), amputation-free survival, limb salvage, complete wound healing, resolution of rest pain, and resolution of CLTI without TLR at 6 and 12 months after the index intervention. Results: Overall, 69 scaffolds were implanted in the 53 lesions, with 100% technical success. There were no deaths within 30 days of the index procedure. The primary patency rates at 6 and 12 months were 95% and 86%, respectively. The corresponding rates of freedom from CD-TLR were 98% and 93%, respectively. Freedom from major amputation was 98% at both time points, and amputation-free survival was 93% and 85% at 6 and 12 months after the index procedure. Wound healing occurred in 31 patients (79%) with Rutherford category 5/6 ischemia by the end of 12 months. Conclusion: The Absorb BVS demonstrated good 1-year patency and clinical outcomes in CLTI patients with complex infrapopliteal disease.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Kum S, Ipema J, Chun-Yin DH, et al. Early and Midterm Experience With the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold in Asian Patients With Chronic Limb-Threatening Ischemia: One-Year Clinical and Imaging Outcomes From the DISAPEAR Registry. J Endovasc Ther. 2020. PMID: 32469296. doi:10.1177/1526602820922524

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。